The Bulletin
The Times


.

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

  • Written by The Bulletin

HONG KONG SAR - Media OutReach - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that Phase III clinical trial of SinoMab's flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.

Read more: SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab)...

hacklink hack forum hacklink film izle hacklink jojobetjojobetz library frDeneme bonusu veren siteler 2026Deneme bonusu veren siteler 2026Grandpashabetmarsbahis girişbetparkaresbetgrandpashabettarafbetmaxwin girişjojobetcasibomholiganbetcasibomcasino siteleriGrandpashabetjojobetgrandpashabetjojobetgrandpashabetholiganbet